<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 06 May 2021 23:25:24 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>读新闻 涨知识 I FDA批准keytruda HER2阳性胃癌一线适应症</title><link>https://mp.weixin.qq.com/s/V-1285yf54nJkdhAk8zzUA</link><description></description><content:encoded><![CDATA[读新闻 涨知识 I FDA批准keytruda HER2阳性胃癌一线适应症]]></content:encoded><pubDate>Thu, 06 May 2021 22:30:23 +0800</pubDate></item><item><title>胃癌一线治疗传喜讯！FDA加速批准帕博利珠单抗用于HER2阳性胃癌</title><link>https://mp.weixin.qq.com/s/DyEhUvCmEE9qxylRB2MCuw</link><description></description><content:encoded><![CDATA[胃癌一线治疗传喜讯！FDA加速批准帕博利珠单抗用于HER2阳性胃癌]]></content:encoded><pubDate>Thu, 06 May 2021 22:30:23 +0800</pubDate></item><item><title>A+学院 | 李晓静教授：血友病个体化治疗新时代</title><link>https://mp.weixin.qq.com/s/o5rga3072J8-eu3MwLHkxw</link><description></description><content:encoded><![CDATA[A+学院 | 李晓静教授：血友病个体化治疗新时代]]></content:encoded><pubDate>Thu, 06 May 2021 22:30:23 +0800</pubDate></item><item><title>【2816】【中国好声音】邵志敏教授&amp;王中华教授团队：CDK4/6抑制剂哌柏西利可提高PARP抑制剂对三阴性乳腺癌的疗效</title><link>https://mp.weixin.qq.com/s/UjGRJA5ssZ4QxE7oT9WewA</link><description></description><content:encoded><![CDATA[【2816】【中国好声音】邵志敏教授&王中华教授团队：CDK4/6抑制剂哌柏西利可提高PARP抑制剂对三阴性乳腺癌的疗效]]></content:encoded><pubDate>Wed, 05 May 2021 18:05:44 +0800</pubDate></item><item><title>一例洛拉替尼耐药患者经化疗后再上布格替尼的基因变化</title><link>https://mp.weixin.qq.com/s/wvKU5uKIeupqG62mlKuEdw</link><description></description><content:encoded><![CDATA[一例洛拉替尼耐药患者经化疗后再上布格替尼的基因变化]]></content:encoded><pubDate>Wed, 05 May 2021 18:05:44 +0800</pubDate></item><item><title>【NPJ Breast Cancer】AKT抑制剂Capivasertib联合氟维司群治疗PTEN突变ER阳性乳腺癌初现活性</title><link>https://mp.weixin.qq.com/s/MhU8bhmOo77FDaDAtsjd_A</link><description></description><content:encoded><![CDATA[【NPJ Breast Cancer】AKT抑制剂Capivasertib联合氟维司群治疗PTEN突变ER阳性乳腺癌初现活性]]></content:encoded><pubDate>Wed, 05 May 2021 18:05:44 +0800</pubDate></item><item><title>CDE I 多发性骨髓瘤药物临床试验中检测微小残留病的技术指导原则（征求意见稿）</title><link>https://mp.weixin.qq.com/s/SlttaeJw4mL-ZJ4ZEpA0wQ</link><description></description><content:encoded><![CDATA[CDE I 多发性骨髓瘤药物临床试验中检测微小残留病的技术指导原则（征求意见稿）]]></content:encoded><pubDate>Tue, 04 May 2021 16:56:54 +0800</pubDate></item><item><title>【巅峰对话】崔传亮教授解读CSCO尿路上皮癌指南更新亮点，指南为基优化个体化治疗策略</title><link>https://mp.weixin.qq.com/s/IQ3ZEmHYbObxBceyB9F1iw</link><description></description><content:encoded><![CDATA[【巅峰对话】崔传亮教授解读CSCO尿路上皮癌指南更新亮点，指南为基优化个体化治疗策略]]></content:encoded><pubDate>Mon, 03 May 2021 20:48:30 +0800</pubDate></item><item><title>2021 CSCO指南会 | 转移性胃癌治疗指南更新解读</title><link>https://mp.weixin.qq.com/s/fYmbmIlMjQuepZddZTJ54g</link><description></description><content:encoded><![CDATA[2021 CSCO指南会 | 转移性胃癌治疗指南更新解读]]></content:encoded><pubDate>Mon, 03 May 2021 20:48:30 +0800</pubDate></item><item><title>【2815】AOO丨CLDN18.2靶点新药，Zolbetuximab或突破胃癌一线治疗疗效瓶颈</title><link>https://mp.weixin.qq.com/s/uE0GcmLUnDNMOHC7cqcS6g</link><description></description><content:encoded><![CDATA[【2815】AOO丨CLDN18.2靶点新药，Zolbetuximab或突破胃癌一线治疗疗效瓶颈]]></content:encoded><pubDate>Mon, 03 May 2021 20:48:30 +0800</pubDate></item><item><title>看新闻 涨知识 I FDA对PD-1/L-1加速审批验证研究投票结果揭晓</title><link>https://mp.weixin.qq.com/s/e_e-LJI8YNHxSqt3fl6L0w</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I FDA对PD-1/L-1加速审批验证研究投票结果揭晓]]></content:encoded><pubDate>Sun, 02 May 2021 20:28:07 +0800</pubDate></item><item><title>2021CSCO指南会｜前列腺癌诊疗指南更新要点解读</title><link>https://mp.weixin.qq.com/s/vhF3RdGx1tYPQPTFov_fXQ</link><description></description><content:encoded><![CDATA[2021CSCO指南会｜前列腺癌诊疗指南更新要点解读]]></content:encoded><pubDate>Sun, 02 May 2021 20:28:07 +0800</pubDate></item><item><title>“2+5”，中国黑色素瘤研究团队7项研究亮相2021 ASCO</title><link>https://mp.weixin.qq.com/s/RCR4zFhFXq4_PE69kAVRww</link><description></description><content:encoded><![CDATA[“2+5”，中国黑色素瘤研究团队7项研究亮相2021 ASCO]]></content:encoded><pubDate>Sun, 02 May 2021 20:28:07 +0800</pubDate></item><item><title>2021ASCO来袭，中国血液相关研究抢先知！</title><link>https://mp.weixin.qq.com/s/REVm60o8S_MneU6esbwpSw</link><description></description><content:encoded><![CDATA[2021ASCO来袭，中国血液相关研究抢先知！]]></content:encoded><pubDate>Sun, 02 May 2021 20:28:07 +0800</pubDate></item><item><title>CDE I 溶瘤病毒产品药学研究与评价技术指导原则（征求意见稿）</title><link>https://mp.weixin.qq.com/s/papndoc1V-TI4ZIVZTHK5g</link><description></description><content:encoded><![CDATA[CDE I 溶瘤病毒产品药学研究与评价技术指导原则（征求意见稿）]]></content:encoded><pubDate>Sat, 01 May 2021 17:50:47 +0800</pubDate></item><item><title>【ASCO 2021】壁报讨论专场的中国好声音——14项研究入选</title><link>https://mp.weixin.qq.com/s/jn-qhlg2zxFGys7sSS5jjw</link><description></description><content:encoded><![CDATA[【ASCO 2021】壁报讨论专场的中国好声音——14项研究入选]]></content:encoded><pubDate>Sat, 01 May 2021 17:50:47 +0800</pubDate></item><item><title>景红梅教授点评｜一例伊沙佐米治疗多发性骨髓瘤病例分享</title><link>https://mp.weixin.qq.com/s/mQVue4jMoQEOspnx68gqnA</link><description></description><content:encoded><![CDATA[景红梅教授点评｜一例伊沙佐米治疗多发性骨髓瘤病例分享]]></content:encoded><pubDate>Sat, 01 May 2021 17:50:47 +0800</pubDate></item><item><title>读NEJM 涨知识 I 溶瘤病毒治疗儿童高分级胶质瘤</title><link>https://mp.weixin.qq.com/s/kkjOm3twIs760poZxvlUZQ</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I 溶瘤病毒治疗儿童高分级胶质瘤]]></content:encoded><pubDate>Fri, 30 Apr 2021 12:24:52 +0800</pubDate></item><item><title>武田注射用维拉苷酶α获批进入中国</title><link>https://mp.weixin.qq.com/s/5bgGe-HS9dapMwsbW3UWsA</link><description></description><content:encoded><![CDATA[武田注射用维拉苷酶α获批进入中国]]></content:encoded><pubDate>Fri, 30 Apr 2021 12:24:52 +0800</pubDate></item><item><title>速度关注！这5项研究将亮相2021 ASCO年会全体大会</title><link>https://mp.weixin.qq.com/s/C0uj-zzEii5VIRyPhXqkuA</link><description></description><content:encoded><![CDATA[速度关注！这5项研究将亮相2021 ASCO年会全体大会]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:19:51 +0800</pubDate></item></channel></rss>